HLB and Peptron Hit New Lows... May Disrupt Second-Half K-Bio Investment Sentiment

HLB and Peptron, key players in South Korea's biotech sector, fell to new lows on Thursday as concerns over regulatory setbacks and research disputes unsettled investors. HLB's U.S. subsidiary received a regulatory notice from the FDA over manufacturing compliance issues, marking its third failed drug approval attempt. Peptron's stock plummeted after clarifications revealed its joint research with Eli Lilly did not involve a key compound, dampening market optimism about its drug delivery platform. Analysts warn these short-term shocks could ripple across the entire biotech industry.